Zoetis

YTD

ALL

Trade Zoetis 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About ZTS

Zoetis, Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health technology. It operates through the United States and International geographical segments.

CEO

Kristin C. Peck

CEOKristin C. Peck

Employees

14,500

Employees14,500

Headquarters

Parsippany, New Jersey

HeadquartersParsippany, New Jersey

Founded

1952

Founded1952

Employees

14,500

Employees14,500

ZTS Key Statistics

Market cap

32.56B

Market cap32.56B

Price-Earnings ratio

12.80

Price-Earnings ratio12.80

Dividend yield

2.69%

Dividend yield2.69%

Average volume

3.44M

Average volume3.44M

High today

$79.28

High today$79.28

Low today

$77.76

Low today$77.76

Open price

$78.40

Open price$78.40

Volume

2.94M

Volume2.94M

52 Week high

$145.04

52 Week high$145.04

52 Week low

$68.77

52 Week low$68.77

Stock Snapshot

With a market cap of 32.56B, Zoetis(ZTS) trades at $78.64. The stock has a price-to-earnings ratio of 12.80 and currently yields dividends of 2.69%.

During the trading session on 2026-10-30, Zoetis(ZTS) shares reached a daily high of $79.28 and a low of $77.76. At a current price of $78.64, the stock is +1.1% higher than the low and still -0.8% under the high.

Trading volume for Zoetis(ZTS) stock has reached 2.94M, versus its average volume of 3.44M.

The stock's 52-week range extends from a low of $68.77 to a high of $145.04.

ZTS News

Zacks 7h

Zoetis Ascends While Market Falls: Some Facts to Note

Zoetis (ZTS Quick QuoteZTS - Free Report) closed the most recent trading day at $78.80, moving +1.29% from the previous trading session. This change outpa...

Simply Wall St 1d

Zoetis Stock Looks Reasonable Despite Its 61% Five Year Slide

has had a tough run on the market in recent years, which naturally raises the question of whether the current share price lines up with what the business earns....

Simply Wall St 4d

Zoetis Could Be 13% Below Fair Value After FDA Approval

Advertisement FDA approval for Convenia RTU puts Zoetis in focus Zoetis (ZTS) received FDA approval for Convenia RTU for Dogs, a single-dose injectable antibi...

Analyst ratings

72%

of 18 ratings

Buy

27.8%

Hold

72.2%

Sell

More ZTS News

Simply Wall St 5d

FDA Dog Antibiotic Approval Could Be A Game Changer For Zoetis Stock

Zoetis reported that the FDA has approved Convenia RTU for Dogs, a more concentrated cefovecin injectable that provides up to 14 days of treatment for susceptib...

Simply Wall St 6d

What Does Zoetis FDA Approval Mean For Its Dog Antibiotic Growth?

Zoetis (NYSE:ZTS) received FDA approval for Convenia RTU for Dogs, a long acting injectable antibiotic for canine skin infections. The new formulation is more...

People also own

Based on the portfolios of people who own ZTS. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.